{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T06:20:40Z","timestamp":1791181240257,"version":"4.1.0"},"reference-count":41,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2014,4,1]],"date-time":"2014-04-01T00:00:00Z","timestamp":1396310400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,4,1]],"date-time":"2014-04-01T00:00:00Z","timestamp":1396310400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gastrojournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gastroenterology"],"published-print":{"date-parts":[[2014,4]]},"DOI":"10.1053\/j.gastro.2013.12.025","type":"journal-article","created":{"date-parts":[[2013,12,18]],"date-time":"2013-12-18T13:00:41Z","timestamp":1387371641000},"page":"941-949.e2","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":175,"title":["Increased Risk of Malignancy With Adalimumab Combination Therapy, Compared With Monotherapy, for Crohn's Disease"],"prefix":"10.1053","volume":"146","author":[{"given":"Mark T.","family":"Osterman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William J.","family":"Sandborn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Frederic","family":"Colombel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne M.","family":"Robinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Winnie","family":"Lau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bidan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul F.","family":"Pollack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roopal B.","family":"Thakkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James D.","family":"Lewis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1053\/j.gastro.2013.12.025_bib1","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1097\/00054725-200207000-00002","article-title":"Long-term evolution of disease behavior of Crohn's disease","volume":"8","author":"Cosnes","year":"2002","journal-title":"Inflamm Bowel Dis"},{"key":"10.1053\/j.gastro.2013.12.025_bib2","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1136\/gut.2004.045294","article-title":"Impact of the increasing use of immunosuppressants in Crohn's disease on the need for intestinal surgery","volume":"54","author":"Cosnes","year":"2005","journal-title":"Gut"},{"key":"10.1053\/j.gastro.2013.12.025_bib3","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1053\/j.gastro.2009.04.063","article-title":"Time trends in therapies and outcomes for adult inflammatory bowel disease, Northern California","volume":"137","author":"Herrinton","year":"2009","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2013.12.025_bib4","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1056\/NEJMoa0904492","article-title":"Infliximab, azathioprine, or combination therapy for Crohn's disease","volume":"362","author":"Colombel","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1053\/j.gastro.2013.12.025_bib5","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1053\/j.gastro.2006.02.014","article-title":"Infliximab plus azathioprine for steroid-dependent Crohn's disease patients: a randomized placebo-controlled trial","volume":"130","author":"Lemann","year":"2006","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2013.12.025_bib6","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1053\/j.gastro.2008.03.004","article-title":"Withdrawal of immunosuppression in Crohn's disease treated with scheduled infliximab maintenance: a randomized trial","volume":"134","author":"Van Assche","year":"2008","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2013.12.025_bib7","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/j.1365-2036.2009.04027.x","article-title":"Clinical trial: benefits and risks of immunomodulators and maintenance infliximab for IBD-subgroup analyses across four randomized trials","volume":"30","author":"Lichtenstein","year":"2009","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1053\/j.gastro.2013.12.025_bib8","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1136\/gut.2010.212712","article-title":"Usefulness of co-treatment with immunomodulators in patients with inflammatory bowel disease treated with scheduled infliximab maintenance therapy","volume":"59","author":"Sokol","year":"2011","journal-title":"Gut"},{"key":"10.1053\/j.gastro.2013.12.025_bib9","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1111\/apt.12076","article-title":"Does co-treatment with immunosuppressors improve outcome in patients with Crohn's disease treated with adalimumab?","volume":"36","author":"Reenaers","year":"2012","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1053\/j.gastro.2013.12.025_bib10","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1136\/gut.2004.049460","article-title":"Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine","volume":"54","author":"Kandiel","year":"2005","journal-title":"Gut"},{"key":"10.1053\/j.gastro.2013.12.025_bib11","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1016\/S0140-6736(09)61302-7","article-title":"Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study","volume":"374","author":"Beaugerie","year":"2009","journal-title":"Lancet"},{"key":"10.1053\/j.gastro.2013.12.025_bib12","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.cgh.2009.11.024","article-title":"Increased risk for non-melanoma skin cancer in patients with inflammatory bowel disease","volume":"8","author":"Long","year":"2010","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2013.12.025_bib13","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1053\/j.gastro.2011.07.039","article-title":"Increased risk of nonmelanoma skin cancers among individuals with inflammatory bowel disease","volume":"141","author":"Singh","year":"2011","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2013.12.025_bib14","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1053\/j.gastro.2012.05.004","article-title":"Risk of melanoma and non-melanoma skin cancer among patients with inflammatory bowel disease","volume":"143","author":"Long","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2013.12.025_bib15","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1053\/j.gastro.2011.06.050","article-title":"Increased risk for nonmelanoma skin cancers in patients who receive thiopurines for inflammatory bowel disease","volume":"141","author":"Peyrin-Biroulet","year":"2011","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2013.12.025_bib16","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.cgh.2012.10.038","article-title":"Long-term outcome of patients with Crohn's disease who respond to azathioprine","volume":"11","author":"Camus","year":"2013","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2013.12.025_bib17","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1093\/aje\/kws375","article-title":"Use of azathioprine and the risk of cancer in inflammatory bowel disease","volume":"177","author":"Pasternak","year":"2013","journal-title":"Am J Epidemiol"},{"key":"10.1053\/j.gastro.2013.12.025_bib18","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1016\/j.cgh.2009.01.004","article-title":"Risk of lymphoma associated with combination anti-tumor necrosis factor and immunomodulator therapy for the treatment of Crohn's disease: a meta-analysis","volume":"7","author":"Siegel","year":"2009","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2013.12.025_bib19","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1038\/ajg.2012.89","article-title":"A pooled analysis of infections, malignancy, and mortality in infliximab- and immunomodulator-treated adult patients with inflammatory bowel disease","volume":"107","author":"Lichtenstein","year":"2012","journal-title":"Am J Gastroenterol"},{"key":"10.1053\/j.gastro.2013.12.025_bib20","doi-asserted-by":"crossref","first-page":"2146","DOI":"10.1038\/ajg.2011.283","article-title":"Role of thiopurine and anti-TNF therapy in lymphoma in inflammatory bowel disease","volume":"106","author":"Herrinton","year":"2011","journal-title":"Am J Gastroenterol"},{"key":"10.1053\/j.gastro.2013.12.025_bib21","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.cgh.2010.09.016","article-title":"A systematic review of factors that contribute to hepatosplenic T-cell lymphoma in patients with inflammatory bowel disease","volume":"9","author":"Kotlyar","year":"2011","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2013.12.025_bib22","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1053\/j.gastro.2005.11.030","article-title":"Human anti-tumor necrosis factor monoclonal antibody (Adalimumab) in Crohn's disease: the CLASSIC-I trial","volume":"130","author":"Hanauer","year":"2006","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2013.12.025_bib23","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1136\/gut.2006.106781","article-title":"Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC-II trial","volume":"56","author":"Sandborn","year":"2007","journal-title":"Gut"},{"key":"10.1053\/j.gastro.2013.12.025_bib24","doi-asserted-by":"crossref","first-page":"829","DOI":"10.7326\/0003-4819-146-12-200706190-00159","article-title":"Adalimumab induction therapy for Crohn's disease previously treated with infliximab","volume":"146","author":"Sandborn","year":"2007","journal-title":"Ann Intern Med"},{"key":"10.1053\/j.gastro.2013.12.025_bib25","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1053\/j.gastro.2006.11.041","article-title":"Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial","volume":"132","author":"Colombel","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2013.12.025_bib26","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1053\/j.gastro.2012.01.035","article-title":"Adalimumab induces and maintains mucosal healing in patients with Crohn's disease: data from the EXTEND trial","volume":"142","author":"Rutgeerts","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2013.12.025_bib27","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1111\/j.1365-2036.2010.04304.x","article-title":"Adalimumab sustains clinical remission and overall clinical benefit after 2 years of therapy for Crohn's disease","volume":"31","author":"Panaccione","year":"2010","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1053\/j.gastro.2013.12.025_bib28","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1111\/j.1365-2036.2011.04717.x","article-title":"Adalimumab sustains steroid-free remission after 3 years of therapy for Crohn's disease","volume":"34","author":"Kamm","year":"2011","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1053\/j.gastro.2013.12.025_bib29","unstructured":"SEER. Surveillance, Epidemiology, and End Results Database. Program public-use data, SEER 17 Regs (2000-2007), released April 2010 based on the November 2009 submission. Available at: http:\/\/seer.cancer.gov. Acessed November 2009."},{"key":"10.1053\/j.gastro.2013.12.025_bib30","series-title":"Incidence of non-melanoma skin cancer in the United States. NIH Pub. no. 83-2433","author":"Scotto","year":"1983"},{"key":"10.1053\/j.gastro.2013.12.025_bib31","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1002\/pds.2046","article-title":"Cancer risk with tumor necrosis factor alpha (TNF) inhibitors: meta-analysis of randomized controlled trials of adalimumab, etanercept, and infliximab using patient level data","volume":"20","author":"Askling","year":"2011","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1053\/j.gastro.2013.12.025_bib32","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1136\/annrheumdis-2011-201244","article-title":"Adalimumab: long-term safety in 23,458 patients from global clinical trials in rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn's disease","volume":"72","author":"Burmester","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1053\/j.gastro.2013.12.025_bib33","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1016\/j.cgh.2008.03.014","article-title":"Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: meta-analysis of placebo-controlled trials","volume":"6","author":"Peyrin-Biroulet","year":"2008","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2013.12.025_bib34","first-page":"A178","article-title":"Safety of infliximab and other Crohn's disease therapies - TREAT registry data with nearly 20,000 patient-years of follow-up","volume":"132","author":"Lichtenstein","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2013.12.025_bib35","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1136\/ard.2010.149419","article-title":"Malignancies associated with tumour necrosis factor inhibitors in registries and prospective observational studies: a systematic review and meta-analysis","volume":"70","author":"Mariette","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1053\/j.gastro.2013.12.025_bib36","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1111\/j.1365-2036.2008.03766.x","article-title":"Screening differences and risk of cervical cancer in inflammatory bowel disease","volume":"28","author":"Huftless","year":"2008","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1053\/j.gastro.2013.12.025_bib37","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.cgh.2011.01.021","article-title":"Risk of nonmelanoma skin cancer in patients with inflammatory bowel disease who use thiopurines is not increased","volume":"9","author":"van Schaik","year":"2011","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2013.12.025_bib38","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1002\/art.37740","article-title":"Tumor necrosis factor alpha inhibitor therapy and cancer risk in chronic immune mediated diseases","volume":"65","author":"Haynes","year":"2013","journal-title":"Arthritis Rheum"},{"key":"10.1053\/j.gastro.2013.12.025_bib39","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.3899\/jrheum.100041","article-title":"Pharmacologic immunomodulation and cutaneous malignancy in rheumatoid arthritis, psoriasis, and psoriatic arthritis","volume":"37","author":"Krathen","year":"2010","journal-title":"J Rheumatol"},{"key":"10.1053\/j.gastro.2013.12.025_bib40","doi-asserted-by":"crossref","first-page":"2886","DOI":"10.1002\/art.22864","article-title":"Biologic treatment of rheumatoid arthritis and the risk of malignancy: analyses from a large US observational study","volume":"56","author":"Wolfe","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1053\/j.gastro.2013.12.025_bib41","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1136\/ard.2004.033993","article-title":"Risks of solid cancers in patients with rheumatoid arthritis and after treatment with tumour necrosis factor antagonists","volume":"64","author":"Askling","year":"2005","journal-title":"Ann Rheumatic Dis"}],"container-title":["Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S001650851301809X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S001650851301809X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T09:41:33Z","timestamp":1762162893000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S001650851301809X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,4]]},"references-count":41,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2014,4]]}},"alternative-id":["S001650851301809X"],"URL":"https:\/\/doi.org\/10.1053\/j.gastro.2013.12.025","relation":{},"ISSN":["0016-5085"],"issn-type":[{"value":"0016-5085","type":"print"}],"subject":[],"published":{"date-parts":[[2014,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Increased Risk of Malignancy With Adalimumab Combination Therapy, Compared With Monotherapy, for Crohn's Disease","name":"articletitle","label":"Article Title"},{"value":"Gastroenterology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.gastro.2013.12.025","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 AGA Institute. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}